WHY AFIRMA

Complex Landscape:

Thyroid nodule diagnosis is challenging

Arriving at an accurate diagnosis and treatment plan requires comprehensive information

ATA guidelines recommend more individualized care, as “…risk stratification is the cornerstone of individualized thyroid cancer management”²

Afirma enables individualized care and is supported by both ATA and NCCN guidelines

The Afirma Platform:

A unified and simple solution for all of your patients

Gain accurate and clinically actionable results from the first FNA

Comprehensive answers, confident decision-making, and personalized treatment

Afirma Genomic Sequencing Classifier:

Conclusively rule out surgery

Clinically validated

Afirma GSC is clinically validated against histopathology results from a blinded, multicenter, prospective cohort

Real-world proven

Afirma GSC results are highly reproducible in real-world and independent studies^5–10

Dependable Hürthle cell distinction

Hürthle cells are dominant in more than 20 percent of indeterminate nodules^7,9 and have been challenging to classify as high or low risk¹¹
Afirma GSC classifies Hürthle cell lesions with high sensitivity

FOR HÜRTHLE CELL DOMINANT NODULES:

Trusted diagnostic certainty with Afirma GSC

Afirma Xpression Atlas (XA):

Confidently tailor treatment

Inform selection of surgical and therapeutic decisions

Afirma XA is informed by TCGA and extensive published literature to form a comprehensive panel^* comprised of:

Afirma XA includes the most common and emerging variants and fusions associated with thyroid carcinoma, such as:

Afirma XA detects variants and fusions that may inform targeted therapy, such as:

*Levels of clinical relevance may vary based on specific variant/fusion identified by Afirma XA

For detailed literature reference of specific variants and fusions, refer to www.afirma.com/XA

Ordering Afirma Xpression Atlas is as simple as checking a box on your Afirma Test Requisition Form

Afirma GSC and Xpression Atlas:

Count on a simplified experience for your patients and your practice

Veracyte is committed to providing patient access regardless of financial situation

Covered by Medicare with no copayment¹²
Covered in-network by most commercial payers (over 260 million patients)¹²
The Veracyte Access Program supports both uninsured and commercially insured patients with financial need¹²

Get answers quickly¹², reduce worry and wait

All-inclusive collection kit
Afirma GSC and XA on the same test requisition form

The Veracyte portal and mobile app

Easily receive, manage, and search electronic patient reports
Access the Veracyte portal at: portal.veracyte.com
Download the Veracyte app from your mobile app store

References: 1. Patel KN, et al. JAMA Surg. 2018. 2. Haugen BR, et al. Thyroid 2016. 3. Bongiovanni M, et al. Acta Cytol. 2012. 4. Shanik M, et al. ENDO 2018. 5. Ahmed S, et al. Endocr. Pract. 2018. 6. Endo M, et al. Thyroid 2018. 7. Harrell RM, et al. Endocr. Pract. 2018. 8. Livhits MJ, et al. Thyroid 2018. 9. Marqusee E, et al. Thyroid 2018. 10. San Martin VT, Nasr CE. Thyroid 2018. 11. Hao Y, et al. BMC Syst. Biol. 2019. 12. Data On File.